OncoSec Medical Incorporated

OTCPK:ONCS.Q Stock Report

Market Cap: US$805.0k

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

OncoSec Medical Past Earnings Performance

Past criteria checks 0/6

OncoSec Medical's earnings have been declining at an average annual rate of -1.6%, while the Biotechs industry saw earnings growing at 17.4% annually.

Key information

-1.56%

Earnings growth rate

52.14%

EPS growth rate

Biotechs Industry Growth17.04%
Revenue growth raten/a
Return on equityn/a
Net Marginn/a
Last Earnings Update31 Jan 2023

Recent past performance updates

No updates

Recent updates

Seeking Alpha Oct 04

OncoSec to cut workforce by 45% as part of corporate restructuring

OncoSec Medical (NASDAQ:ONCS) on Tuesday said it would reduce its workforce by about 45% as part of a restructuring intended to focus expenses on the development of its lead clinical candidate Tavo. The company is evaluating Tavo in a phase 2b trial called KEYNOTE-695 for the treatment of metastatic melanoma, the most serious type of skin cancer. "Since joining as CEO my focus has been on reviewing all aspects of our technology and pipeline. This led to the conclusion that an operational restructuring and strategic pipeline refocus is the best course of action," ONCS top boss Robert Arch said in a statement. The company said results of the KEYNOTE-695 trial's secondary goal was expected in Q4 of this year, while results from the main goal was expected in Q1 2023. ONCS stock earlier closed -2% at $0.49.
Analysis Article Jan 28

What Type Of Shareholders Make Up OncoSec Medical Incorporated's (NASDAQ:ONCS) Share Registry?

If you want to know who really controls OncoSec Medical Incorporated ( NASDAQ:ONCS ), then you'll have to look at the...

Revenue & Expenses Breakdown

How OncoSec Medical makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

OTCPK:ONCS.Q Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Jan 230-291122
31 Oct 220-321024
31 Jul 220-341126
30 Apr 220-381328
31 Jan 220-411529
31 Oct 210-421531
31 Jul 210-451534
30 Apr 210-421234
31 Jan 210-431332
31 Oct 200-461729
31 Jul 200-421825
30 Apr 200-411822
31 Jan 200-381720
31 Oct 190-321419
31 Jul 190-301218
30 Apr 190-351521
31 Jan 190-381720
31 Oct 180-411919
31 Jul 180-391917
30 Apr 180-331614
31 Jan 180-271212
31 Oct 170-221012
31 Jul 170-211012
30 Apr 170-221012
31 Jan 170-241113
31 Oct 160-251114
31 Jul 160-271215
30 Apr 160-271215
31 Jan 160-271116
31 Oct 150-241014
31 Jul 150-21813
30 Apr 150-18711
31 Jan 150-1679
31 Oct 140-1468
31 Jul 140-1266
30 Apr 140-1055
31 Jan 140-844
31 Oct 130-743
31 Jul 130-743
30 Apr 130-743
31 Jan 130-643
31 Oct 120-733

Quality Earnings: ONCS.Q is currently unprofitable.

Growing Profit Margin: ONCS.Q is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: ONCS.Q is unprofitable, and losses have increased over the past 5 years at a rate of 1.6% per year.

Accelerating Growth: Unable to compare ONCS.Q's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ONCS.Q is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-42.7%).


Return on Equity

High ROE: ONCS.Q's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/06/28 10:07
End of Day Share Price 2023/06/28 00:00
Earnings2023/01/31
Annual Earnings2022/07/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

OncoSec Medical Incorporated is covered by 9 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James MolloyAlliance Global Partners
Thomas ShraderBTIG
Raghuram SelvarajuH.C. Wainwright & Co.